The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

The firm reported positive results this week from a biomarker analysis in a Phase IIb trial of OST-HER2, which it will submit to regulators.

The announcement comes on the heels of promising preliminary Phase II data, in which OCU410 reduced lesion growth in patients' eyes.

The grant will support a Phase I study of an anti-CD64 CAR T-cell therapy in patients with acute myeloid leukemia.

The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in ...

The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...

The partners want to develop personalized therapeutics and diagnostics based on insights derived from the Middle Eastern biorepository.

At the JP Morgan Healthcare Conference, the firm highlighted two antibody-drug conjugates among 10 programs that will fuel ...

The firm hopes to become a commercial-stage company this year, if the KIT inhibitor bezuclastinib is approved by the FDA as expected.

The firm said at the JP Morgan Healthcare Conference that a pivotal Phase III study, testing daraxonrasib in RAS-mutant ...

The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.